Mesoblast (MESO) has released an update.
Mesoblast Limited is poised for a potential FDA approval for Ryoncil, aimed at treating children with acute GVHD, after a successful BLA resubmission. The company also progresses with a Phase 3 trial for chronic inflammatory low back pain and seeks accelerated FDA approval for Revascor in heart failure patients. Amid these advancements, Mesoblast has effectively reduced its cash expenditure, maintaining a robust cash balance while prioritizing key programs and preparing for Ryoncil’s commercial launch.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.
